Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 3014

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Osteoarthritis
  • Pain
  • Tissue
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3014

License Grant
The Company has the licensing right for drugs that were designed for the treatment of post-menopausal women.
License Property
Lasofoxifene is a selective estrogen receptor modulator being developed to prevent osteoporosis in postmenopausal women in Phase III trials. The drug has been found to reduce bone loss and lower cholesterol levels without the breast or uterine cancer risks common in hormonal therapies.
Field of Use
Lasofoxifene (Fablyn®) is a product candidate that resulted from our collaboration with the Licensee. The Licensee submitted an NDA and an MAA for Fablyn for osteoporosis treatment in December 2007 and January 2008, respectively. The FDA Advisory Committee in September 2008 voted 9-3 in favor of approving this drug. In January 2009, the Licensee received a complete response letter from the FDA requesting additional information for Fablyn. In February 2009, Fablyn received approval in the EU for the treatment of osteoporosis.

IPSCIO Record ID: 1011

License Grant
The Company granted to Licensee an exclusive, nontransferable, worldwide license to develop, make, have made, use, sell, have sold, import and export a novel formulation of lasofoxifene intended for an under served market in women’s health.
Field of Use
Lasofoxifene is an estrogen partial agonist for osteoporosis treatment and other diseases. The oral, 0.5 mg form of lasofoxifene tartrate was developed under the trade name Fablyn.

IPSCIO Record ID: 60407

License Grant
Licensee is marketing bazedoxifene under the brand names Viviant and Conbriza in various territories for the treatment of postmenopausal osteoporosis. Licensee is responsible for the registration and worldwide marketing of bazedoxifene.
License Property
Bazedoxifene is a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue.
Field of Use
Licensee has combined bazedoxifene with the active ingredient in Premarin to create Duavee, a combination therapy for the treatment of post-menopausal symptoms in women. Duavee is approved in the United States and it is anticipated that it will be marketed under the brand name Duavive in the EU.

IPSCIO Record ID: 4723

License Grant
The Licensor announced a License Agreement with the Licensee for oral lasofoxifene for the United States and additional territories.
License Property
Lasofoxifene is an estrogen partial agonist for the treatment of osteoporosis and other diseases.
Field of Use
The Licensee is a specialty pharmaceutical company focused on late-stage women’s health products.

IPSCIO Record ID: 28618

License Grant
Licensor hereby grants to Swiss Licensee and its Affiliates an exclusive, royalty-bearing license in the Territory, with the right to sublicense, under Celgene Patent Rights, Licensor's interest in Joint Patent Rights and Know-How of Licensor to develop, make, have made, use, sell, offer for sale and import Products in all Fields of Use, and non-exclusive, non-transferable, royalty-free research license in the Territory under Licensor Patent Rights, Licensor's interest in Joint Patent Rights and Know-How of Licensor solely for the purpose of conducting research on Research Compounds, Active Compounds, Candidate Compounds, Final Selected Compounds and Back-Up Compounds in all Fields of Use; provided, however, that:

Licensor and its Affiliates developed expertise and acquired proprietary rights related to selective estrogen receptor modulator compounds ('SERMS') which are selective for Estrogen Receptor ('ER')(alpha) ('ER(alpha)') in U2OS cells (the 'ER(alpha)SELECTIVITY'

License Property
SP500263  Series  shall mean  Licensor's  proprietary  compounds claimed in U.S. Patent Application  Serial No.  09/475,776
Field of Use
Additional Field shall mean the treatment, prevention and diagnosis of a disease or disorder, other than a disease or disorder within the Primary Field or the Oncology Field.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.